Nifedipine Tablets

Nifedipine is a dihydropyridine calcium antagonist that selectively inhibits the transmembrane transport of calcium ions into myocardial cells and smooth muscle cells, and inhibits the release of calcium ions from intracellular pools without changing the plasma calcium ion concentration. Pharmacological action This product can simultaneously relax the coronary arteries in the normal blood supply area and the ischemic area, antagonize spontaneous or ergonovine-induced coronary artery spasm, increase the delivery of myocardial oxygen in patients with coronary artery spasm, and relieve and prevent coronary artery spasm. It can also inhibit myocardial contraction, reduce myocardial metabolism, and reduce myocardial oxygen consumption. On the other hand, it can relax peripheral resistance vessels, reduce peripheral resistance, reduce systolic and diastolic blood pressure, and reduce cardiac afterload. This product can delay the sinus node function and atrioventricular conduction of isolated hearts; electrophysiological studies of whole animals and humans have not found that this product has the effect of delaying atrioventricular conduction, prolonging the recovery time of the sinus node, and slowing down the sinus node rate. Toxicological action Carcinogenicity, mutagenicity and reproductive toxicity No carcinogenicity. No mutagenicity. Large doses can reduce the fertility of female mice, cause teratogenesis, and induce abortion (increased drug absorption rate in fetal mice, increased fetal mortality, and decreased survival rate of newborn mice). Pregnant monkeys taking 2/3-2 times the maximum human dose can cause small placenta and chorionic dysplasia; giving rats 3 times the maximum human dose can cause prolonged pregnancy.

Nifedipine.

This product is a capsule, and the contents are brown particles.

1. Hypertension (alone or in combination with other antihypertensive drugs). 2. Angina pectoris: especially variant angina pectoris.

1. Swallow the whole tablet on an empty stomach. Do not chew or break it apart before taking. 2. Start with a small dose. The initial dose is 20 mg/time, and the maximum dose is 60 mg/time, once a day. The maximum daily dose does not exceed 120 mg. 3. The dose of nifedipine should be gradually adjusted depending on the patient's tolerance and the control of angina pectoris. The patient's blood pressure needs to be monitored before increasing the dose. If the patient's symptoms are obvious, the dose adjustment period can be shortened according to the patient's response to the drug. 4. No "rebound" symptoms were observed when the drug was discontinued, but the dose still needs to be gradually reduced and the patient's condition should be closely observed. 5. The dose of ordinary preparations can be safely replaced with the dose of sustained-release preparations. For example: 30 mg/time of ordinary preparations, three times a day, can be replaced with 90 mg/time of sustained-release preparations, once a day.

1 Common adverse reactions include peripheral edema (proportional to the dose); headache, etc. 2 Adverse reactions with uncertain relationship to this product: dizziness; nausea; constipation; fatigue; facial flushing and heat sensation. 31%-3% adverse reactions: chest pain; leg pain; paresthesia; vertigo; rash; leg cramps; nosebleeds; rhinitis; impotence; frequent urination, etc. 41% adverse reactions: cellulitis; chills; facial edema; neck pain; pelvic pain; atrial fibrillation; bradycardia; cardiac arrest; premature beats; hypotension; palpitations; phlebitis; postural hypotension; tachycardia; anxiety; loss of libido; depression; insomnia; lethargy; pruritus; night sweats; abdominal pain; diarrhea; dry mouth; indigestion; esophagitis; bloating; gastrointestinal bleeding; vomiting; lymphadenopathy; gout; weight loss; arthralgia; arthritis; myalgia; dyspnea; cough; pharyngitis; blurred vision; amblyopia; conjunctivitis; diplopia; kidney stones, etc. 5 Rare adverse reactions: allergic hepatitis; alopecia; anemia; antinuclear antibody positive arthritis; erythromelalgia; peeling. 6 Exfoliative dermatitis; fever; gingival hyperplasia; male breast development; leukopenia; mood swings; muscle pain; nervousness; purpura; tremor; sleep disorders; Stevens-Johnson syndrome; syncope; thrombocytopenia; toxic epidermal fusion necrosis; instant blindness at peak blood drug concentration; tremor; urticaria, etc.

It is contraindicated in patients allergic to nifedipine.

Precautions for children: Not clear yet. Precautions for pregnancy and lactation: 1. No detailed clinical research data. Nifedipine is clinically used for pregnant women with hypertension. 2. Nifedipine can be secreted into breast milk, so lactating women should stop taking the drug or stop breastfeeding. Precautions for the elderly: The half-life of nifedipine is prolonged in the elderly, so pay attention to adjusting the dose when using it.

1. Combined with nitrates, it controls angina attacks and has good tolerance. 2. Combined with beta-blockers, most patients have good tolerance and efficacy for this product, but some patients may induce and aggravate hypotension, heart failure and angina. 3. Combined with digitalis, it may increase the blood digoxin concentration, suggesting that the blood concentration of digoxin should be monitored when using it for the first time, adjusting the dose or discontinuing this product. 4. Combined with drugs with high protein binding rate, such as dicoumarins, phenytoin sodium, quinidine, quinine, warfarin, etc., the free concentrations of these drugs often change. 5. Combined with cimetidine, the peak plasma concentration of this product increases, pay attention to adjust the dose. 6. When grapefruit juice is taken with this product, the Cmax and AUC of this product increase.

Keep in a light-proof and airtight container.

10 mg

36 months.

Nanjing Baijingyu Pharmaceutical Co., Ltd.

• Founded in:

  1991-07-12

• Address:

  No. 1 Huizhong Road, Nanjing Economic and Technological Development Zone

• Tax NO.:

  9132019213490905XY

• Registered Funds:

  61.7764 million yuan

• Website:

  Log in to view

• Email:

  Log in to view